4,870 Shares in Cencora, Inc. (NYSE:COR) Bought by Brookstone Capital Management

Brookstone Capital Management purchased a new stake in Cencora, Inc. (NYSE:COR) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 4,870 shares of the company’s stock, valued at approximately $1,183,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Vanguard Group Inc. acquired a new stake in Cencora during the fourth quarter worth about $4,212,508,000. PNC Financial Services Group Inc. acquired a new stake in shares of Cencora during the 4th quarter worth approximately $51,339,000. Los Angeles Capital Management LLC bought a new stake in shares of Cencora during the first quarter valued at approximately $45,692,000. Pensioenfonds Rail & OV acquired a new position in shares of Cencora in the first quarter valued at $37,371,000. Finally, Ferguson Wellman Capital Management Inc. bought a new position in Cencora in the first quarter worth $32,609,000. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Cencora Trading Down 1.2 %

Shares of COR opened at $225.30 on Friday. The company has a debt-to-equity ratio of 3.41, a quick ratio of 0.53 and a current ratio of 0.89. The company has a market cap of $44.94 billion, a price-to-earnings ratio of 24.65, a PEG ratio of 1.65 and a beta of 0.48. The stock has a fifty day moving average price of $229.12 and a two-hundred day moving average price of $227.82. Cencora, Inc. has a 52-week low of $171.65 and a 52-week high of $246.75.

Cencora (NYSE:COR) last released its quarterly earnings results on Wednesday, May 1st. The company reported $3.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.65 by $0.15. Cencora had a return on equity of 268.67% and a net margin of 0.67%. The business had revenue of $68.41 billion during the quarter, compared to analysts’ expectations of $70.60 billion. During the same period in the previous year, the business posted $3.50 earnings per share. The firm’s revenue for the quarter was up 7.8% compared to the same quarter last year. Analysts predict that Cencora, Inc. will post 13.44 EPS for the current fiscal year.

Cencora Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, May 24th. Investors of record on Friday, May 10th were issued a $0.51 dividend. This represents a $2.04 dividend on an annualized basis and a dividend yield of 0.91%. The ex-dividend date was Thursday, May 9th. Cencora’s dividend payout ratio is currently 22.32%.

Insider Buying and Selling

In other news, major shareholder Walgreens Boots Alliance, Inc. sold 1,859,390 shares of Cencora stock in a transaction on Wednesday, May 22nd. The stock was sold at an average price of $215.12, for a total value of $399,991,976.80. Following the completion of the sale, the insider now directly owns 24,418,171 shares of the company’s stock, valued at approximately $5,252,836,945.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, major shareholder Walgreens Boots Alliance, Inc. sold 1,859,390 shares of the firm’s stock in a transaction dated Wednesday, May 22nd. The shares were sold at an average price of $215.12, for a total value of $399,991,976.80. Following the transaction, the insider now owns 24,418,171 shares of the company’s stock, valued at approximately $5,252,836,945.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Steven H. Collis sold 10,754 shares of Cencora stock in a transaction that occurred on Tuesday, April 16th. The stock was sold at an average price of $237.48, for a total transaction of $2,553,859.92. Following the sale, the chief executive officer now owns 285,088 shares of the company’s stock, valued at approximately $67,702,698.24. The disclosure for this sale can be found here. Insiders sold 1,956,675 shares of company stock worth $422,352,056 in the last quarter. Insiders own 15.80% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on COR. SVB Leerink restated an “outperform” rating and issued a $275.00 price objective on shares of Cencora in a research note on Thursday. StockNews.com cut shares of Cencora from a “strong-buy” rating to a “buy” rating in a research note on Thursday, May 2nd. Robert W. Baird upped their price objective on Cencora from $275.00 to $277.00 and gave the company an “outperform” rating in a research note on Thursday, May 2nd. Finally, Citigroup raised their target price on Cencora from $265.00 to $280.00 and gave the stock a “buy” rating in a research report on Tuesday, April 30th. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, Cencora has a consensus rating of “Moderate Buy” and an average price target of $235.30.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.